Navigation Links
Drug May Ease Angina in People With Type 2 Diabetes

SUNDAY, March 10 (HealthDay News) -- The drug Ranexa (ranolazine) may help reduce chest pain in people with type 2 diabetes, a new study finds.

The drug is approved in the United States for treatment of chronic angina (chest pain), but this is the first study to evaluate it in patients with diabetes, heart disease and angina, according to the researchers.

One expert not connected to the study said the findings are welcome news for patients.

The study "demonstrates that ranolazine is very effective in reducing angina in those with type 2 diabetes and, interestingly, is more effective in those with higher blood sugars," said Dr. Howard Weintraub, clinical associate professor in the department of medicine at NYU Langone Medical Center in New York City.

People with diabetes are at increased risk for heart disease, and people with heart disease and diabetes are more likely to have angina than those without diabetes, the researchers noted.

The study included more than 900 patients who received either 1,000 milligrams of Ranexa or an inactive placebo twice a day for eight weeks. The patients had type 2 diabetes, heart disease and at least one angina episode a week, and were already taking one or two other anti-angina drugs.

Between weeks two and eight of the study, patients taking Ranexa had an average of 3.8 angina episodes per week, compared with 4.3 episodes per week for those taking the placebo. Patients taking the drug used 1.7 doses of nitroglycerin per week, compared with 2.1 doses per week among those in the placebo group. Nitroglycerin is commonly used to treat or prevent episodes of chest pain in people who have coronary artery disease (narrowing of the blood vessels that supply blood to the heart).

The study was scheduled for presentation Sunday at the annual meeting of the American College of Cardiology in San Francisco. It was also published online the same day in the Journal of the American College of Cardiology and will appear in the journal's May 21 print issue.

The study was funded by Gilead Sciences, Inc., which makes Ranexa.

"Angina is associated with worse quality of life, increased risk of hospitalization and higher health care costs, and appears to be more prevalent in patients with diabetes," study lead author Dr. Mikhail Kosiborod, associate professor of medicine at the University of Missouri, Kansas City, and a cardiologist at St. Luke's Mid America Heart Institute, said in a meeting news release.

"While ranolazine was shown to be effective in reducing angina in prior studies, this is the first time it has been prospectively evaluated in patients with diabetes -- a high-risk and therapeutically challenging group," he added.

The study also found that Ranexa had the strongest effect in reducing angina episodes among patients with poor blood sugar control. Prior research has shown that the drug may lower fasting glucose levels in people with diabetes.

"Ranolazine is an effective anti-anginal drug in patients with diabetes and may also have a glucose [blood sugar]-lowering effect," Kosiborod said. "If the glucose-lowering action of ranolazine is confirmed in future studies, patients with diabetes and angina may derive a dual benefit from this drug."

Weintraub agreed. "As the focus of the treatment of angina in diabetics increasingly focuses on [drug] therapy, this may offer another choice in optimal medical care in this group of patients," he said.

The majority of the study patients were men (61 percent). Ninety-six percent had high blood pressure and 74 percent had a history of heart attack. Most patients were taking cholesterol-lowering statins (82 percent) and heart drugs such as ACE inhibitors (88 percent). Sixteen percent were smokers.

About 347 million people worldwide have diabetes and about 90 percent of those people have type 2 diabetes. The main causes of type 2 diabetes are believed to be excess weight and lack of physical activity. One in three American adults could have the condition by the year 2050, according to the U.S. Centers for Disease Control and Prevention.

More information

The U.S. National Institute of Diabetes and Digestive and Kidney Diseases has more about diabetes.

-- Robert Preidt

SOURCES: Howard Weintraub, M.D., clinical associate professor, department of medicine, Leon H. Charney division of cardiology, NYU Langone Medical Center, New York City; American College of Cardiology, news release, March 10, 2013

Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Enzyme explains angina in diabetics
2. Normal triglyceride levels in people of African descent may hinder diagnosis of metabolic syndrome
3. Anxiety Might Help People Sniff Out Threats
4. People Carrying Guns May Appear Bigger Than They Are
5. CT Scans Deliver More Radiation to Obese People: Study
6. Good intentions bring mixed results for Haitis disabled people
7. Migraines More Likely for People With Celiac Disease, Study Says
8. People Love Talking About Themselves, Brain Scans Show
9. Older People With Dementia Cared for Mostly at Home
10. People With HIV at Higher Odds of Sudden Cardiac Death
11. People Who Lived Near World Trade Center Report More Lung Disease
Post Your Comments:
Related Image:
Drug May Ease Angina in People With Type 2 Diabetes
(Date:6/26/2016)... , ... June 26, 2016 , ... PawPaws brand ... new product that was developed to enhance the health of felines. The formula is ... The two main herbs in the PawPaws Cat Kidney Support Supplement Soft ...
(Date:6/25/2016)... , ... June 25, 2016 , ... Austin residents seeking ... American College of Mohs Surgery and to Dr. Russell Peckham for medical and surgical ... effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern ... Laude and his M.D from the David Geffen School of Medicine at UCLA. He ... Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... people are unfamiliar with. The article goes on to state that individuals are now ... of these less common operations such as calf and cheek reduction. The Los Angeles ...
(Date:6/24/2016)... ... 2016 , ... The Pulmonary Hypertension Association (PHA) learned during ... two significant new grants to support its work to advance research and patient ... recognizing patients, medical professionals and scientists for their work in fighting pulmonary hypertension ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on ... today announced that patient enrollment in its ongoing ... Duchenne) has exceeded 50% of its 24-patient target. ... in the third quarter of 2016, and to ...
(Date:6/23/2016)... the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered in Bogota. Colombia ... ... Sandra ... ... Astellas is a pharmaceutical company ...
(Date:6/23/2016)... , June 23, 2016  Experian Health, ... and transforming the patient payment and care ... innovative new products and services that will ... revenue cycle offerings. These award-winning solutions will ... workflows, remain compliant in an ever-changing environment ...
Breaking Medicine Technology: